Dr Enrica Alteri has extensive experience in drug discovery and clinical safety and worked at the European Medicines Agency for 8 years, serving on its Executive Board Prof Jeffrey Skopek is Associate ...
A reliable supply of consistent and physiologically relevant motor neurons is fundamental to the study and screening of potential treatments for motor neuron diseases ioMotor Neurons also offer an ...
CAMBRIDGE, England, February 19, 2026--(BUSINESS WIRE)--Following a record Q4 in sales volume and the successful closing of $50 million in new funding, bit.bio is leveraging its economies of scale to ...
In the mid-2000s, Mark Kotter, MD, PhD, was running a lab studying oligodendrocytes when he started his training in neurosurgery. As a neurosurgeon, he had access to rare brain samples and was able to ...
The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing. As a Ginkgo Technology Network ...
bit.bio, the global leader in cell programming technology, today announced the successful closing of a $30 million financing round led by M&G Investments, a leading international savings and ...
BlueRock Therapeutics, a clinical-stage cell therapy company, and bit.bio, a synbio firm, signed a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T ...
The life sciences industry is challenged by a lack of reliable, reproducible cell models that generate translatable, reflective, data of actual human disease. ioGlutamatergic Neurons HTT 50CAGWT aims ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results